查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1946399

思觉失调症药物类别、给药途径、地区及竞争格局划分，2021-2031年）

Schizophrenia Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Route Of Administration, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球思觉失调症治疗市场预计将从 2025 年的 64.5 亿美元成长到 2031 年的 84.8 亿美元，复合年增长率为 4.67%。

该市场涵盖一系列抗精神病药物和辅助性治疗，旨在控制这些慢性精神障碍的阳性症状、阴性症状和认知症状。推动这一成长的关键因素包括：全球精神障碍盛行率的上升、长效注射剂（LAI）製剂的日益普及（提高了患者依从性），以及医疗基础设施的不断完善，从而提高了诊断和治疗率。国际药品製造商协会联合会（IFPMA）的报告显示，到2025年，全球将有约10亿人受到某种形式的精神疾病的影响，这将显着增加对有效治疗性介入和先进药物解决方案的需求。

市场概览
预测期 2027-2031
市场规模：2025年 64.5亿美元
市场规模：2031年 84.8亿美元
复合年增长率：2026-2031年 4.67%
成长最快的细分市场 口服
最大的市场 北美洲

然而，该市场面临许多挑战，包括用药依从性低以及许多现有疗法存在严重的副作用。患者常因METABOLIC INC.症候群和体重增加等副作用而停止治疗，这可能导致疾病復发，并因住院治疗而增加经济负担。其他挑战还包括新药研发成本高昂、监管核准流程严格以及学名药药对过期品牌药的竞争造成的商业性侵蚀。因此，製造商必须克服这些复杂的临床和经济挑战，才能在全球竞争激烈的市场环境中维持长期成长。

市场驱动因素

针对全新作用机制的新型治疗方法的问世，标誌着市场格局的根本性转变，其治疗范围超越了传统的多巴胺受体拮抗剂，涵盖了更广泛的疾病。毒蕈碱促效剂的出现凸显了这种转变，这类药物在提供疗效的同时，也能减少传统抗精神病药物通用的代谢副作用。製造商正积极开发这些药物，以惠及更广泛的患者群体。正如勃林格殷格翰在2024年5月的新闻稿中所指出的，思觉失调症影响着全球约2,400万人，这为这些创新化合物创造了庞大的目标族群。这些突破性治疗方法的商业性潜力正在推动大量投资，而百时美施贵宝在2024年3月以140亿美元收购Karuna Therapeutics的交易，更凸显了这些新一代治疗方法的高市场价值。

同时，长效注射剂的日益普及正在重塑市场竞争格局，为解决药物依从性低这一普遍难题提供了一个切实可行的方案。这些给药系统将每日口服片剂的给药频率降低至每月或每半年註射一次，显着改善了患者的治疗效果，并降低了与復发相关的住院率。医疗机构优先选择这些製剂，以确保稳定的生物利用度并简化疾病管理通讯协定，从而为主要市场参与者创造了稳定的收入来源。例如，强生公司在2024年10月报告称，其Invega Sustena和Invega Hafiela产品线的全球销售额在第三季度达到10.5亿美元，表明该公司将继续依赖长效治疗方案来实现持续成长。

市场挑战

目前抗精神病药物治疗的持续不遵从性和严重的副作用，对全球思觉失调症治疗市场的扩张构成了重大障碍。患者常遭受严重的副作用，包括代谢症候群和显着的体重增加，严重降低其生活品质和身体健康。这些耐受性问题往往导致治疗中断，阻碍后续治疗，并加剧復发率。因此，该市场以间歇性用药模式而非稳定的长期用药为特征，这使得製造商无法充分挖掘已确诊患者群体的商业性潜力，并限制了可持续的收入成长。

这种身体健康负担的直接影响是可量化的且十分严重的，降低了目标市场的整体永续性和稳定性。根据世界卫生组织（世卫组织）2025年的数据，思觉失调症患者的平均寿命比一般人群短约9年，这种差异主要由合併的躯体疾病（例如心血管疾病和代谢性疾病）造成。这种高死亡率，加上药物的代谢副作用，抑制了患者群体的扩大，并为市场渗透创造了严峻的挑战。

市场趋势

将数位疗法应用于药物依从性监测和症状管理是全球思觉失调症治疗市场的变革性趋势，它提供了一种非药物治疗方案，可以满足诸如阴性症状等未被满足的需求。与传统药物疗法不同，这些基于软体的介入措施将患者与实证治疗技术直接连接起来，即时追踪患者的依从性，同时着重改善其认知和动机。随着製造商寻求利用能够改变疾病进展的数位工具来提高药物疗效，这种方法正获得显着的关注。勃林格殷格翰于2025年10月报告称，其在研处方数位疗法CT-155已证实，将数位技术与标准抗精神病药物疗法相结合具有临床疗效，在CAINS-MAP量表上，阴性症状严重程度显着改善了6.8分。

同时，经皮给药系统的扩展正在丰富治疗选择，使其不再局限于口服片剂和长效注射剂，尤其是在提高生物利用度和减少副作用方面。经皮吸收贴片能够持续、可控地释放抗精神病药物，从而减轻口服给药时常见的血浆峰谷浓度波动，而这种波动往往是导致副作用的原因。这种给药方式能够让看护者直观地确认患者的用药依从性，并且无需注射这种侵入性手段，即可解决思觉失调症治疗中的一大难题。根据Alto Neuroscience公司截至2025年3月的财年财务报告，该公司的新型经皮製剂ALTO-101展现出比口服製剂更高的全身药物暴露量，同时显着降低了该类药物常见的不利事件，这表明贴剂技术有望提高治疗指数。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球思觉失调症药物市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依药物类别（第一代、第二代、第三代药物）
    • 给药途径（注射、口服）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美思觉失调症药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国家分析
    • 我们
    • 加拿大
    • 墨西哥

7. 欧洲思觉失调症药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

8. 亚太地区思觉失调症药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

9. 中东和非洲思觉失调症药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东和非洲：国家分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲思觉失调症药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国家分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 司机
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 最新进展

第十三章 全球思觉失调症药物市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的可能性
  • 供应商电力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Alkermes Plc
  • Eli Lilly and Company.
  • Johnson & Johnson.
  • AstraZeneca.
  • Pfizer Inc.
  • AbbVie Inc.
  • Otsuka Pharmaceutical Inc.
  • Bristol-Myers Squibb Company.
  • Sumitomo Dainippon Pharma.
  • Acadia Pharmaceuticals.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 19876

The Global Schizophrenia Drugs Market is projected to expand from USD 6.45 Billion in 2025 to USD 8.48 Billion by 2031, registering a compound annual growth rate of 4.67%. This market encompasses a variety of antipsychotic medications and adjunctive therapies aimed at managing the positive, negative, and cognitive symptoms of this chronic psychiatric disorder. Key drivers of this growth include the rising global prevalence of mental health conditions, the increasing uptake of long-acting injectable (LAI) formulations that enhance patient adherence, and the development of healthcare infrastructure that supports improved diagnosis and treatment rates. As reported by the International Federation of Pharmaceutical Manufacturers & Associations, approximately one billion people globally were affected by a mental health condition in 2025, creating a substantial and rising demand for effective therapeutic interventions and advanced pharmacological solutions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 6.45 Billion
Market Size 2031USD 8.48 Billion
CAGR 2026-20314.67%
Fastest Growing SegmentOral
Largest MarketNorth America

However, the market confronts significant barriers related to medication non-adherence and the harsh side effect profiles associated with many existing treatments. Patients frequently discontinue therapy due to adverse reactions such as metabolic syndrome and weight gain, which often leads to disease relapse and increases the economic burden of hospitalization. Additionally, the high costs of developing novel drugs, rigorous regulatory approval pathways, and the commercial erosion caused by generic competition for patent-expired brands present considerable challenges. Consequently, manufacturers must navigate these complex clinical and economic hurdles to maintain long-term growth within the competitive global landscape.

Market Driver

The introduction of novel therapies targeting new mechanisms of action marks a fundamental shift in the market, moving beyond traditional dopamine receptor antagonism to address a wider range of symptoms. This transition is highlighted by the emergence of muscarinic agonists, which offer efficacy while reducing the metabolic side effects common in older antipsychotics. Manufacturers are aggressively pursuing these assets to secure a larger share of the patient population. As noted by Boehringer Ingelheim in a May 2024 press release, schizophrenia affects approximately 24 million people worldwide, presenting a vast target demographic for these innovative compounds. The commercial potential of such breakthroughs has triggered substantial investment, evidenced by Bristol Myers Squibb's acquisition of Karuna Therapeutics for a total equity value of $14.0 billion in March 2024, underscoring the high market valuation of next-generation treatments.

Concurrently, the increasing adoption of long-acting injectable formulations is reshaping the competitive landscape by offering a practical solution to the pervasive issue of medication non-adherence. By reducing dosing frequency from daily oral tablets to monthly or biannual injections, these delivery systems significantly improve patient outcomes and decrease relapse-associated hospitalization rates. Healthcare providers are prioritizing these formulations to ensure consistent bioavailability and streamline disease management protocols, resulting in robust revenue streams for key market players. For instance, Johnson & Johnson reported in October 2024 that global sales for their Invega Sustenna and Invega Hafyera franchise reached $1.05 billion for the third quarter, demonstrating the sustained and growing reliance on long-acting therapeutic options.

Market Challenge

The persistence of medication non-adherence and severe side effect profiles in current antipsychotic treatments constitutes a critical impediment to the expansion of the Global Schizophrenia Drugs Market. Patients often suffer from debilitating adverse reactions, including metabolic syndrome and significant weight gain, which drastically diminish their quality of life and physical well-being. These tolerability issues frequently drive individuals to discontinue therapy, disrupting the continuity of care and leading to high rates of disease relapse. Consequently, the market is characterized by fragmented consumption patterns rather than steady, long-term adherence, preventing manufacturers from maximizing the commercial potential of the diagnosed patient population and limiting sustained revenue growth.

The direct impact of these physical health burdens is quantifiable and severe, reducing the overall longevity and stability of the addressable market. According to the World Health Organization in 2025, individuals with schizophrenia had a life expectancy approximately nine years shorter than the general population, a disparity largely attributed to co-occurring physical illnesses such as cardiovascular and metabolic diseases. This elevated mortality rate, often exacerbated by the metabolic side effects of pharmacological interventions, restricts the growth of the patient pool and creates a challenging environment for expanding market penetration.

Market Trends

The integration of digital therapeutics for adherence monitoring and symptom management represents a transformative trend in the Global Schizophrenia Drugs Market, offering a non-pharmacological modality to address unmet needs such as negative symptoms. Unlike traditional pharmacotherapy, these software-based interventions deliver evidence-based therapeutic techniques directly to patients to improve cognitive functioning and motivation while tracking medication compliance in real-time. This approach is gaining significant traction as manufacturers seek to augment drug efficacy with digital tools that can modify disease progression. As reported by Boehringer Ingelheim in October 2025, their investigational prescription digital therapeutic CT-155 demonstrated a statistically significant 6.8-point improvement in negative symptom severity on the CAINS-MAP scale, highlighting the clinical viability of combining digital innovations with standard antipsychotic regimens.

Simultaneously, the expansion of transdermal drug delivery systems is diversifying treatment options beyond oral tablets and long-acting injectables, specifically targeting improved bioavailability and reduced side effects. Transdermal patches provide continuous, controlled release of antipsychotic medication, which can mitigate the peak-trough plasma fluctuations often responsible for adverse events in oral dosing. This delivery method also offers a visual confirmation of adherence for caregivers, addressing a critical challenge in schizophrenia management without the invasiveness of injections. According to Alto Neuroscience's March 2025 financial results, their novel transdermal formulation of ALTO-101 exhibited greater systemic drug exposure than the orally administered version while significantly reducing typical class-related adverse events, underscoring the potential of patch-based technologies to enhance therapeutic indices.

Key Market Players

  • Alkermes Plc
  • Eli Lilly and Company.
  • Johnson & Johnson.
  • AstraZeneca.
  • Pfizer Inc.
  • AbbVie Inc.
  • Otsuka Pharmaceutical Inc.
  • Bristol-Myers Squibb Company.
  • Sumitomo Dainippon Pharma.
  • Acadia Pharmaceuticals.

Report Scope

In this report, the Global Schizophrenia Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Schizophrenia Drugs Market, By Drug Class

  • First Generation Drugs
  • Second Generation Drugs
  • Third Generation Drugs

Schizophrenia Drugs Market, By Route Of Administration

  • Injectable
  • Oral

Schizophrenia Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Schizophrenia Drugs Market.

Available Customizations:

Global Schizophrenia Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Schizophrenia Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (First Generation Drugs, Second Generation Drugs, Third Generation Drugs)
    • 5.2.2. By Route Of Administration (Injectable, Oral)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Schizophrenia Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Route Of Administration
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Schizophrenia Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Route Of Administration
    • 6.3.2. Canada Schizophrenia Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Route Of Administration
    • 6.3.3. Mexico Schizophrenia Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Route Of Administration

7. Europe Schizophrenia Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Route Of Administration
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Schizophrenia Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Route Of Administration
    • 7.3.2. France Schizophrenia Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Route Of Administration
    • 7.3.3. United Kingdom Schizophrenia Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Route Of Administration
    • 7.3.4. Italy Schizophrenia Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Route Of Administration
    • 7.3.5. Spain Schizophrenia Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Route Of Administration

8. Asia Pacific Schizophrenia Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Route Of Administration
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Schizophrenia Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Route Of Administration
    • 8.3.2. India Schizophrenia Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Route Of Administration
    • 8.3.3. Japan Schizophrenia Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Route Of Administration
    • 8.3.4. South Korea Schizophrenia Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Route Of Administration
    • 8.3.5. Australia Schizophrenia Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Route Of Administration

9. Middle East & Africa Schizophrenia Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Route Of Administration
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Schizophrenia Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Route Of Administration
    • 9.3.2. UAE Schizophrenia Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Route Of Administration
    • 9.3.3. South Africa Schizophrenia Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Route Of Administration

10. South America Schizophrenia Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Route Of Administration
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Schizophrenia Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Route Of Administration
    • 10.3.2. Colombia Schizophrenia Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Route Of Administration
    • 10.3.3. Argentina Schizophrenia Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Route Of Administration

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Schizophrenia Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Alkermes Plc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Eli Lilly and Company.
  • 15.3. Johnson & Johnson.
  • 15.4. AstraZeneca.
  • 15.5. Pfizer Inc.
  • 15.6. AbbVie Inc.
  • 15.7. Otsuka Pharmaceutical Inc.
  • 15.8. Bristol-Myers Squibb Company.
  • 15.9. Sumitomo Dainippon Pharma.
  • 15.10. Acadia Pharmaceuticals.

16. Strategic Recommendations

17. About Us & Disclaimer